Drug Sales Trends for AZOPT

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for AZOPT

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
AZOPT			2022
AZOPT			2021
AZOPT			2020

AZOPT Market Analysis and Sales Projections: Brinzolamide Ophthalmic Suspension

Last updated: September 1, 2026

AZOPT is Alcon’s branded brinzolamide 1% ophthalmic suspension for lowering elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Its U.S. patent exclusivity has expired, generic brinzolamide is available, and the product is no longer positioned as a high-growth branded asset. The commercial outlook is stable to declining, driven by recurring glaucoma demand but constrained by generic substitution, therapeutic competition, and limited pricing power.

Public filings do not separately disclose AZOPT revenue. The projections below estimate net sales using market-access, volume, and price assumptions rather than reported product revenue.

What is AZOPT and how does brinzolamide work?

AZOPT contains brinzolamide, a topical carbonic anhydrase inhibitor. It reduces aqueous humor formation and lowers intraocular pressure. The product is administered as a 1% ophthalmic suspension, generally three times daily as monotherapy or twice daily when used with other glaucoma medicines, according to the FDA-approved label.[1]

AZOPT product profile

Attribute	Detail
Brand	AZOPT
Active ingredient	Brinzolamide
Strength	1% ophthalmic suspension
Therapeutic class	Topical carbonic anhydrase inhibitor
Indications	Ocular hypertension and open-angle glaucoma
Original U.S. sponsor	Alcon Laboratories
Current commercial owner	Alcon
U.S. regulatory application	NDA 020816
Route	Ophthalmic
Administration	Topical ocular
Primary alternatives	Dorzolamide, timolol, prostaglandin analogs, fixed-combination glaucoma products
FDA approval	1998, according to FDA product records and labeling history[1][2]

Brinzolamide is pharmacologically similar to dorzolamide but has different suspension characteristics and dosing considerations. It is usually prescribed when a carbonic anhydrase inhibitor is clinically appropriate and a patient, physician, or payer favors brinzolamide over dorzolamide.

What is the current market position of AZOPT?

AZOPT occupies a mature, niche position in the glaucoma market. Its commercial value comes from prescription persistence, brand familiarity, and Alcon’s ophthalmology distribution infrastructure rather than patent protection.

The product competes in a crowded category that includes:

• Prostaglandin analogs such as latanoprost, bimatoprost, and travoprost.
• Beta blockers such as timolol.
• Carbonic anhydrase inhibitors such as dorzolamide and brinzolamide.
• Alpha agonists such as brimonidine.
• Fixed combinations such as dorzolamide/timolol and brimonidine/timolol.
• Newer agents, including netarsudil and latanoprostene bunod.

Prostaglandin analogs generally lead first-line treatment because of once-daily dosing and strong intraocular-pressure reduction. AZOPT is more commonly used as an adjunct, an alternative to another carbonic anhydrase inhibitor, or when treatment is individualized around tolerability and adherence.

How large is the addressable market for AZOPT?

The underlying market is substantial because glaucoma and ocular hypertension require long-term treatment. The addressable market for AZOPT is smaller than the total glaucoma market because brinzolamide is one ingredient in a broad multi-class category and has generic competition.

Global glaucoma prevalence was estimated at more than 75 million people in 2020, with projections rising as populations age.[3] Most patients do not receive brinzolamide. A practical commercial segmentation is:

Segment	Relevance to AZOPT
Diagnosed open-angle glaucoma	Core disease population
Ocular hypertension	Secondary labeled population
Patients requiring combination therapy	Important use case
Patients unable to tolerate or adhere to alternatives	Selective opportunity
Patients using generic brinzolamide	Competitive volume pool
Patients using branded AZOPT	Narrow residual segment

The highest-value commercial opportunity is not untreated glaucoma. It is conversion or retention among patients who receive a carbonic anhydrase inhibitor and remain on branded therapy despite generic availability.

What are AZOPT sales and revenue projections?

Alcon does not report AZOPT as a separate revenue line in its public annual filings. The following base-case estimates are therefore modeled product-level sales, not reported Alcon guidance.[4]

Five-year AZOPT sales projection

Fiscal year	Base-case net sales	Growth versus prior year	Key assumption
2024A estimated	$35 million	-	Mature branded product with generic erosion
2025E	$33 million	-6%	Continued U.S. substitution
2026E	$31 million	-6%	Stable chronic demand, lower realized price
2027E	$29 million	-6%	Generic share expansion
2028E	$27 million	-7%	Brand contraction in payer-controlled channels
2029E	$25 million	-7%	Residual branded and international demand

The base case assumes that branded AZOPT retains a small share of brinzolamide prescriptions, with volume declining more slowly than price because glaucoma therapy is chronic and switching is not universal.

Scenario range

Scenario	2025E	2027E	2029E	Principal driver
Upside	$39 million	$38 million	$37 million	Brand retention, supply disruption among generics, stronger international demand
Base case	$33 million	$29 million	$25 million	Gradual generic substitution
Downside	$27 million	$20 million	$15 million	Aggressive payer mandates and additional low-cost suppliers

The commercial risk is asymmetric. A supply shortage affecting generic products could temporarily support AZOPT volume, but long-term generic competition is more likely to reduce both unit share and net price.

What is the expected AZOPT growth rate?

AZOPT is expected to decline at approximately 5% to 8% annually in the base case through 2029. The primary causes are loss of exclusivity, generic substitution, and the availability of alternative glaucoma drug classes.

Sales could be more resilient in markets where:

• Brand prescribing remains common.
• Generic reimbursement is weak or fragmented.
• Alcon has strong ophthalmology-channel access.
• Prescribers prioritize established branded products.
• Local registration or supply barriers limit generic competition.

Sales should decline faster in markets with centralized procurement, mandatory generic substitution, or strong pharmacy-level substitution.

What patents protect AZOPT?

AZOPT’s original U.S. patent estate no longer provides meaningful commercial exclusivity. The 1998 approval places the product well beyond the standard U.S. five-year new chemical entity exclusivity period and beyond the relevant patent term for the original development program.[1][2]

AZOPT patent and exclusivity status

Protection category	Status
New chemical entity exclusivity	Expired
Original formulation protection	Expired or commercially ineffective
U.S. patent exclusivity	No current high-value exclusivity identified from the mature product history
Orange Book blocking position	No current patent barrier expected to prevent generic entry
Pediatric exclusivity	No material current exclusivity expected
Regulatory exclusivity	Expired

The key competitive issue is therefore not patent litigation. It is brand economics, physician preference, formulary placement, and supply reliability.

What is the Orange Book status of AZOPT?

AZOPT is listed in FDA drug databases under NDA 020816. Its original regulatory protection has expired, and the product is exposed to approved generic competition.[1][2]

An Orange Book listing does not itself preserve market exclusivity. Any relevant listed patent must remain unexpired and enforceable, and the generic applicant must address the listed patents through an applicable certification. For a mature AZOPT product, Paragraph IV litigation is not expected to be the primary market event.

Are there Paragraph IV challenges to AZOPT?

No major current Paragraph IV dispute is central to the AZOPT commercial outlook. The product’s generic-entry phase occurred after its original exclusivity period, and the market has moved into post-exclusivity competition.

Generic entry risk

Risk	Assessment
New Paragraph IV challenge	Low commercial significance
Additional generic approvals	Moderate to high
Price erosion	High
Volume erosion	Moderate to high
Authorized generic impact	Possible
Brand-only payer coverage	Weakening
Litigation-driven launch delay	Low

A new ANDA entrant could still affect pricing and channel share, but the value of a patent challenge would be limited because the product is already mature.

Which companies challenge or compete with AZOPT?

AZOPT competes with both branded products and generic manufacturers. The relevant competitive set includes Alcon, Bausch + Lomb, Sandoz, Teva, and other FDA-approved generic suppliers, depending on current market authorizations and supply status.

Direct and indirect competitors

Competitor	Product or class	Competitive effect
Generic brinzolamide suppliers	Brinzolamide 1% suspension	Direct price and substitution pressure
Generic dorzolamide	Carbonic anhydrase inhibitor	Direct therapeutic substitute
Cosopt and generic dorzolamide/timolol	Fixed combination	Reduces need for separate agents
Xalatan and generic latanoprost	Prostaglandin analog	Strong first-line alternative
Lumigan and generic bimatoprost	Prostaglandin analog	Alternative for pressure reduction
Alphagan P and generic brimonidine	Alpha agonist	Adjunctive and alternative therapy
Rhopressa	Netarsudil	Newer adjunctive option
Vyzulta	Latanoprostene bunod	Branded alternative in selected patients

The most important competitor is not another premium brand. It is generic brinzolamide combined with low-cost glaucoma therapies that satisfy payer step-edit requirements.

What formulations are protected by AZOPT?

AZOPT is a suspension rather than a simple aqueous solution. Brinzolamide’s low water solubility requires formulation technology to maintain dose uniformity and ocular tolerability.

The commercially relevant formulation attributes include:

• Brinzolamide 1% concentration.
• Ophthalmic suspension delivery.
• Particle-size control.
• Redispersibility after storage.
• Preservative system.
• Bottle and dropper performance.
• Ocular comfort and dosing consistency.

These formulation characteristics can create manufacturing and regulatory hurdles for generic suppliers. They do not, by themselves, create current patent exclusivity. FDA-approved generics must demonstrate pharmaceutical equivalence and bioequivalence or otherwise satisfy the applicable ophthalmic product requirements.[5]

How strong is the AZOPT patent estate?

The current patent estate is weak as a commercial defense. AZOPT has several residual protections that may matter to product quality or manufacturing, but the central product is not protected by a live exclusivity position capable of supporting premium pricing.

Patent-strength assessment

Factor	Rating	Rationale
Core compound protection	Low	Mature active ingredient
Composition-of-matter protection	Low	Original protection expired
Formulation protection	Low to moderate	Technical barriers may remain, but broad blocking rights are unlikely
Method-of-use protection	Low	Label uses are established and generic entry is available
Manufacturing know-how	Moderate	Suspension quality and scale-up can affect supply
Litigation leverage	Low	No apparent current blocking patent position
Brand equity	Moderate	Alcon ophthalmology presence supports retention
Pricing power	Low	Generic substitution limits net price

Manufacturing know-how may support product consistency, but it is less durable than patent exclusivity and can be replicated by qualified suppliers.

What FDA regulatory issues affect AZOPT?

AZOPT is an approved prescription ophthalmic product. The main regulatory issues are quality, sterility, particulate control, suspension uniformity, preservative performance, labeling, and manufacturing compliance.

For generic suppliers, ophthalmic suspensions can be more technically demanding than simple solutions. FDA scrutiny may focus on:

• Sterility assurance.
• Container-closure integrity.
• Particle-size distribution.
• Dose uniformity.
• Resuspendability.
• Impurity profile.
• Preservative concentration.
• Stability through the labeled shelf life.

These requirements can limit the number of reliable suppliers. They are more likely to support temporary supply stability than long-term branded exclusivity.

What litigation or settlement agreements affect AZOPT?

No material ongoing patent litigation or settlement agreement is required to explain AZOPT’s current market position. The commercial decline is primarily a post-exclusivity market effect.

Any future dispute would more likely concern:

• Manufacturing quality.
• Product liability.
• Advertising or labeling.
• Generic substitution.
• Distribution or supply arrangements.

A patent settlement would have limited strategic value unless a new, enforceable formulation or manufacturing patent were asserted against a specific generic applicant.

Does AZOPT have biosimilar risk?

AZOPT has no biosimilar risk because brinzolamide is a small-molecule drug, not a biologic. The relevant threat is generic ANDA competition under the Hatch-Waxman framework.

This distinction matters commercially:

• Generic approval is generally faster and less costly than biosimilar development.
• Generic suppliers can obtain pharmacy-level substitution.
• No reference-product biologic exclusivity applies.
• Manufacturing competition can expand rapidly once the product is mature.

What licensing deals support AZOPT sales?

AZOPT’s current sales outlook is not dependent on a major newly disclosed licensing transaction. Alcon’s value is based on ownership, commercialization, ophthalmology infrastructure, and portfolio management.

A licensing arrangement could still affect specific territories, but licensing would not restore U.S. patent exclusivity. The most commercially relevant deal structures would involve:

• Regional distribution.
• Co-promotion.
• Tender supply.
• Authorized generic rights.
• Portfolio bundling with other ophthalmic products.

What generic launch scenarios exist for AZOPT?

Scenario 1: Continued gradual erosion

This is the base case. Generic brinzolamide captures additional volume each year, while AZOPT retains patients with brand preference, stable physician prescribing, or limited switching. Net sales decline at a mid-single-digit rate.

Scenario 2: Accelerated payer substitution

Medicare, commercial plans, and pharmacy benefit managers increase mandatory generic substitution. AZOPT loses formulary preference, and annual sales decline by 10% or more for several years.

Scenario 3: Generic supply disruption

A manufacturing interruption or shortage among generic suppliers temporarily increases AZOPT demand. The effect would likely be episodic. It would not change the long-term post-exclusivity trajectory.

Scenario 4: Portfolio defense

Alcon protects ophthalmology-channel access through contracting, physician education, distribution, and combination-product promotion. This could stabilize revenue but would require higher commercial spending and lower net price.

How does AZOPT compare with dorzolamide?

Brinzolamide and dorzolamide are both topical carbonic anhydrase inhibitors. Dorzolamide has a longer generic history and is widely available in standalone and fixed-combination products. AZOPT may retain advantages for selected patients based on tolerability, prescribing familiarity, or suspension characteristics, but these factors do not offset the price advantage of generic dorzolamide.

Factor	AZOPT	Generic dorzolamide
Active ingredient	Brinzolamide	Dorzolamide
Brand status	Branded	Generic
Price position	Premium	Low cost
Dosing	Typically three times daily alone	Typically three times daily alone
Fixed combinations	Less central to current use	Strong presence with timolol
Patent protection	Expired	Expired
Payer preference	Weakening	Generally stronger
Commercial outlook	Declining mature brand	Stable generic demand

What is the investment and commercial outlook for AZOPT?

AZOPT should be valued as a mature cash-flow product rather than a growth asset. Its revenue base can remain durable because glaucoma treatment is chronic, but the brand lacks the structural drivers required for expansion.

Commercial investment conclusions

1. Revenue exposure is modest relative to Alcon’s broader ophthalmology portfolio.
2. Generic competition creates persistent price and volume pressure.
3. Patent litigation is unlikely to produce a meaningful change in the outlook.
4. Manufacturing quality and supply reliability are more important than intellectual-property exclusivity.
5. International markets may decline more slowly where generic substitution is less developed.
6. Brand retention programs can reduce erosion but are unlikely to create sustained growth.
7. The most attractive opportunity is portfolio bundling with newer ophthalmic products, not standalone AZOPT expansion.

Key Takeaways

• AZOPT is brinzolamide 1% ophthalmic suspension for ocular hypertension and open-angle glaucoma.
• U.S. regulatory and patent exclusivity has expired.
• Generic brinzolamide and generic dorzolamide are the principal direct threats.
• Alcon does not separately report AZOPT revenue.
• A modeled 2024 baseline is approximately $35 million in global net sales.
• Base-case sales decline from about $33 million in 2025 to $25 million in 2029.
• Upside depends on generic supply problems, brand retention, and international demand.
• Downside depends on mandatory substitution and further generic entrants.
• AZOPT has no biosimilar risk because brinzolamide is a small molecule.
• The product’s remaining value is operational and commercial, not patent-driven.

FAQs

When did AZOPT lose U.S. market exclusivity?

AZOPT’s original U.S. exclusivity expired years ago. The product was approved in 1998, placing it well beyond the standard new chemical entity exclusivity period.

Can a generic manufacturer launch brinzolamide without infringing AZOPT patents?

Generic entry is already commercially established. Any applicant must address applicable FDA requirements and any unexpired listed patent, but no current blocking patent position is central to AZOPT’s market outlook.

Is AZOPT still covered by Medicare and commercial insurance?

Coverage varies by plan. Generic brinzolamide is generally favored where available, while branded AZOPT may require prior authorization, step therapy, or higher patient cost sharing.

What is the main reason physicians continue prescribing AZOPT?

Continued use can reflect patient stability, physician familiarity, tolerability, prior treatment response, and practical reluctance to switch a chronic ophthalmic regimen.

Could AZOPT sales increase despite generic competition?

Short-term increases are possible if generic supply is disrupted or if Alcon improves retention in selected markets. A sustained global growth cycle is unlikely without a significant change in pricing, reimbursement, or product positioning.

References

1. U.S. Food and Drug Administration. (2024). AZOPT (brinzolamide ophthalmic suspension) prescribing information.
2. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations, NDA 020816.
3. World Health Organization. (2023). World report on vision and eye care.
4. Alcon Inc. (2024). Annual report and Form 10-K.
5. U.S. Food and Drug Administration. (2023). Product-specific guidance for ophthalmic drug products and generic drug development.